March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy
Author Affiliations & Notes
  • Nikolas J. London
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Richard S. Kaiser
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Rayan A. Alshareef
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Mohammed Khuthaila
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Vanessa A. London
    Family Dermatology, Philadelphia, Pennsylvania
  • Omesh P. Gupta
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Jason Hsu
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • James F. Vander
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
    Family Dermatology, Philadelphia, Pennsylvania
  • Marc J. Spirn
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Carl D. Regillo
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  Nikolas J. London, None; Richard S. Kaiser, None; Rayan A. Alshareef, None; Mohammed Khuthaila, None; Vanessa A. London, None; Omesh P. Gupta, None; Jason Hsu, None; James F. Vander, None; Marc J. Spirn, None; Carl D. Regillo, None
  • Footnotes
    Support  Wills Eye Innovation Research Grant
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5789. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nikolas J. London, Richard S. Kaiser, Rayan A. Alshareef, Mohammed Khuthaila, Vanessa A. London, Omesh P. Gupta, Jason Hsu, James F. Vander, Marc J. Spirn, Carl D. Regillo; Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5789.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of low dose oral isotretinoin on recurrent retinal detachment in cases complicated by or at risk for proliferative vitreoretinopathy.

Methods: : Prospective, non-randomized, cohort, with simultaneous, retrospective age-matched, pathology-matched control group. Following retinal detachment repair, patients receive isotretinoin 20mg PO daily for 12 consecutive weeks. There are two study arms: 1) patients with recurrent retinal detachment with proliferative vitreoretinopathy, and 2) patients with primary retinal detachment at high risk for proliferative vitreoretinopathy formation.

Results: : This study is ongoing and preliminary results are reported here. Updated results will be reported at the meeting. In our group with recurrent detachment group associated with proliferative vitreoretinopathy we have recruited 18 and 19 patients in the isotretinoin and control groups, respectively. With a minimum of 3 months of follow-up, the surgical success rate in the isotretinoin group with a single intervention is 85%, compared to 58% in the control group. For patients with primary retinal detachment at high risk for proliferative vitreoretinopathy formation, we have recruited 18 and 73 patients in the isotretinoin and control groups, respectively. In this arm, the surgical success rate in the isotretinoin group with a single intervention was 94%, compared to 68% in the control group. The side effects of the medication have been generally mild, with most patients experiencing only dry lips and/or mouth.

Conclusions: : Isotretinoin shows promise for treating and preventing proliferative vitreoretinopathy. Completion of this study and further randomized studies are needed.

Clinical Trial: : http://www.clinicaltrials.gov NCT01445028

Keywords: retinal detachment • proliferative vitreoretinopathy • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×